Research Article
Mycobacterium tuberculosis H37Rv: In Silico Drug Targets Identification by Metabolic Pathways Analysis
Table 1
Unique pathways of M. tuberculosis when compared to H. sapiens.
| S. no. | Pathway name | Human | Mycobacterium tuberculosis H37Rv |
| 1 | Carbohydrate Metabolism | | | 1.1 | C5-Branched dibasic acid metabolism | Absent | Present | 2 | Energy Metabolism | | | 2.1 | Photosynthesis | Absent | Absent | 2.2 | Carbon fixation pathways in prokaryotes | Absent | Present | 2.3 | Methane metabolism | Absent | Present | 3 | Lipid Metabolism | | | 3.1 | Fatty acid elongation in mitochondria | Present | Absent | 3.2 | Sphingolipid metabolism | Present | Absent | 3.3 | Arachidonic acid metabolism | Present | Absent | 4 | Nucleotide Metabolism | All Present | All Present | 5 | Amino Acid Metabolism | All Present | All Present | 6 | Metabolism of Other Amino Acids | All Present | All Present | 6.1 | Phosphonate and phosphinate metabolism | Absent | Absent | 7 | Glycan Biosynthesis and Metabolism | | | 7.1 | N-Glycan biosynthesis | Present | Absent | 7.2 | Various types of N-glycan biosynthesis | | Absent | 7.3 | Mucin type O-Glycan biosynthesis | Present | Absent | 7.4 | Other types of O-glycan biosynthesis | Present | Absent | 7.5 | Glycosaminoglycan biosynthesis—chondroitin sulfate | Present | Absent | 7.6 | Glycosaminoglycan biosynthesis—heparan sulfate | Present | Absent | 7.7 | Glycosaminoglycan biosynthesis—keratan sulfate | Present | Absent | 7.8 | Glycosaminoglycan degradation | Present | Absent | 7.9 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | Present | Absent | 7.10 | Glycosphingolipid biosynthesis—lacto and neolacto series | Present | Absent | 7.11 | Glycosphingolipid biosynthesis—globo series | Present | Absent | 7.12 | Glycosphingolipid biosynthesis—ganglio series | Present | Absent | 7.13 | Lipopolysaccharide biosynthesis | Absent | Present | 7.14 | Peptidoglycan biosynthesis | Absent | Present | 7.15 | Other Glycan degradation | Present | Absent |
|
|